Hopital Cardiologique
- Address
- lock Available on a paid plan
Cardiovascular Disease Research
The team at Hopital Cardiologique is evaluating innovative approaches to lower the risk of heart attack and stroke in patients with high cardiovascular risk. Studies include the use of novel lipid‑lowering antibodies and oral agents that may improve heart muscle recovery after an acute event.
- Evaluation of long‑term safety of lipid‑lowering antibodies
- Assessment of heart‑remodeling therapies after myocardial infarction
- Investigation of novel anticoagulant strategies for secondary prevention
- Comparative effectiveness of metabolic agents in cardiac patients
These trials aim to reduce cardiovascular events and improve cardiac function by testing new therapies and refining existing treatment pathways.
Oncology Clinical Trials
A broad oncology program focuses on advanced lung cancers and other solid tumors, testing cutting‑edge targeted agents such as non‑small cell lung cancer therapies and drugs directed at KRAS G12C mutations. Researchers also explore antibody‑drug conjugates for HER2‑positive disease.
- Development of targeted therapy combinations for lung cancer
- Evaluation of antibody‑drug conjugates in solid tumors
- KRAS‑directed inhibitor studies across multiple cancer types
- Integration of immunotherapy with novel agents
The purpose of these studies is to improve response rates and survival for patients with difficult‑to‑treat cancers by introducing more precise and effective treatments.
Respiratory Disease Research
The site conducts trials aimed at chronic lung conditions, including cystic fibrosis and severe asthma with an eosinophilic phenotype, as well as preventative strategies against COVID‑19. Efforts are directed toward long‑term disease control and reduction of acute exacerbations.
- Long‑term modulators for cystic fibrosis patients
- Biologic therapies for eosinophilic asthma
- Antibody prophylaxis to prevent symptomatic COVID‑19
- Novel treatment regimens for advanced lung cancer subtypes
These investigations seek to enhance quality of life, decrease hospitalizations, and provide new preventive options for respiratory illnesses.
Metabolic and Nutritional Research
Studies address the intersection of metabolic health and cardiovascular outcomes, evaluating agents such as dapagliflozin for their ability to support heart function after myocardial injury and to manage metabolic risk factors.
- Effects of SGLT2 inhibitors on cardiac remodeling post‑MI
- Metabolic management strategies in high‑risk cardiac patients
- Interaction of nutrition‑related pathways with heart disease
- Assessment of metabolic endpoints in cardiovascular trials
The goal is to integrate metabolic therapies into cardiovascular care, improving overall patient outcomes and reducing disease progression.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 39 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Daiichi Sankyo Inc.2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Daiichi Sankyo Inc.2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hopital Cardiologique
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy of Dapagliflozin on Cardiac Systolic Function and Remodeling in Acute Myocardial Infarction Patients with Left Ventricular Dysfunction | Assistance Publique Hopitaux De Paris | Phase III | Not Recruiting | Nov 2024 | — |
IMP list
lock Showing 1 of 39 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adagrasib | 2 | Unknown | 2020-12-23 | 2020-12-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.